BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Univar Solutions Inc. , Oak Street Health , Seagen Inc. , U.S. Xpress Enterprises, Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.

Univar Solutions Inc. (NYSE - UNVR)

Under the terms of the agreement, Univar will be acquired by funds managed by affiliates of Apollo (NYSE – APO) (the "Apollo Funds") in an all-cash transaction that values the Company at an enterprise value of approximately $8.1 billion. The agreement provides that Univar Solutions shareholders will receive $36.15 per share in cash. The investigation concerns whether the Univar Solutions Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the Apollo Funds are paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/univar-solutions-inc-nyse-unvr/ .

U.S. Xpress Enterprises, Inc. (NYSE – USX)

Under the terms of the agreement, U.S. Express will be acquired by Knight-Swift Transportation Holdings Inc. (NYSE - KNX) ("Knight-Swift"). U.S. Xpress stockholders will receive $6.15 per share in an all-cash transaction, representing an enterprise value of approximately $808 million.
The investigation concerns whether the U.S. Xpress Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Knight-Swift is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/u-s-xpress-enterprises-inc-nyse-usx/ .

Oak Street Health (NYSE – OSH)

Under the terms of the deal, Oak Street Health will be acquired by CVS Health® ("CVS") (NYSE - CVS). Oak Street Health stockholders will receive $39.00 per share in an all-cash transaction, representing an enterprise value of approximately $10.6 billion. The investigation concerns whether the Oak Street Health Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether CVS is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/oak-street-health-nyse-osh/ .

Seagen Inc. (Nasdaq - SGEN)

Under the terms of the agreement, Seagen will be acquired by Pfizer Inc. (NYSE - PFE). Pfizer will pay $229.00 in cash for each share of Seagen common stock in a deal with an enterprise value of approximately $43 billion. The investigation concerns whether the Seagen Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Pfizer is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/seagen-inc-nasdaq-sgen/ .

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

PFE
The Conversation (0)
Arvinas and Pfizer Announce Upcoming Vepdegestrant  Poster Presentations at the 2023 European Society for Medical Oncology  Breast Cancer Annual Congress

Arvinas and Pfizer Announce Upcoming Vepdegestrant Poster Presentations at the 2023 European Society for Medical Oncology Breast Cancer Annual Congress

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Vepdegestrant is a novel investigational PROTAC ® estrogen receptor... Keep Reading...
Pfizer Reports First-Quarter 2023 Results

Pfizer Reports First-Quarter 2023 Results

First-Quarter 2023 Revenues of $18.3 Billion Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1 Billion Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew... Keep Reading...
XTANDI®  plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

XTANDI® plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Results show the potential for XTANDI to add to the standard of care in prostate cancer, if approved Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki... Keep Reading...
U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

PREVNAR 20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine, helping to protect against all 20 serotypes contained in the vaccine PREVNAR 20 builds on PREVNAR 13 ® and includes seven additional serotypes shown to be associated with antibiotic resistance,... Keep Reading...
Pfizer Declares Second-Quarter 2023 Dividend

Pfizer Declares Second-Quarter 2023 Dividend

Board of Directors approves quarterly cash dividend of $0.41 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company's common stock, payable June 9, 2023, to holders of the Common Stock of record at the close of... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2025

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...

Latest Press Releases

Related News